Hemanext

Hemanext is a global biomedical technology company focused on transfusion medicine. Founded in 1997 by Martin Cannon, it has become a leader in red blood cell (RBC) storage and transfusion technologies, holding over 200 patents and receiving FDA and CE Mark approvals for its products. The company's flagship product, Hemanext ONE, is the first FDA-authorized technology designed to mitigate the red blood cell storage lesion. It uses hypoxic storage methods to preserve the quality and viability of RBCs, enhancing patient outcomes and reducing healthcare costs. Hemanext's services center on advanced blood processing, storage, and transfusion technologies that optimize the therapeutic impact of RBCs. Hemanext is committed to enabling safer transfusions and healthier patients by collaborating with the transfusion medicine community. The company works with healthcare providers, blood banks, and organizations involved in transfusion medicine, including participation in initiatives like the Sickle Cell Disease Association of America's SCD C.A.R.E.S. Consortium.

• Employees 36
• Founded 2004
• Total Funding $96120000